& Miller, E
Disclosure of interest: FAM, KG, VR, MK, WNW, KB, PH have nothing to disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P1005 - ESOC25-1187 PREVALENCE AND OUTCOME OF CEREBRAL MICROBLEEDS IN ANTIPHOSPHOLIPID SYNDROME Jonathan Naftali 1 , Rani Barnea 1 , Ruth Eliahou 1 , Tzippy Shochat 1 , Adi Wilf-Yarkoni 1 , Sivan Bloch 2 , Michael Findler 1 , Avi Leader 3 , Walid Saliba 2 , Eitan Auriel 1 1 Rabin medical center, Tel Aviv University, Petah Tikva, Israel, 2 Carmel medical center, Haifa, Israel, 3 Memorial Sloan Kettering Cancer Center, New-York, United States Background and Aims: Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by arterial and venous thrombosis
These benefits include supporting healthy detoxification, promoting a healthy immune system, and moderating oxidative stress levels.* Glutathione is also essential for brain function, metabolic and biochemical reactions such as DNA synthesis and repair, and is critical in supporting the health of organs such as the lungs and kidneys.*
The copper peptide might also be helpful in treating telogen effluvium, the type of diffuse shedding triggered by stress, illness, surgery, hormonal changes, nutritional deficiencies or significant weight loss
Once reconstituted with bacteriostatic water, peptide solutions typically remain stable for 28 days at refrigerator temperature
